Education
About Us
Working with TipRanks
Follow Us
Laekna, Inc. (HK:2105)
:2105
Lae102 Intravenous Administration, Lae102 Subcutaneous Administration, Lae102 Multiple Subcutaneous Administration
Overweight And Obese Volunteers
Phase I
Recruiting
Evaluate LAE102 in Healthy and Overweight/Obese Subjects
Jun 03, 2024
―
Afuresertib
Breast Cancer
Phase III
Recruiting
Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Apr 13, 2021
―
Paclitaxel, Afuresertib
Platinum-Resistant Ovarian Cancer
Phase II
Completed
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Apr 02, 2020
―
Lae001
Prostate Cancer Metastatic
Phase I/II
Terminated
A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
Jan 29, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Laekna, Inc. (2105) have in its pipeline
2105 is currently developing the following drugs: Lae102 Intravenous Administration, Lae102 Subcutaneous Administration, Lae102 Multiple Subcutaneous Administration, Afuresertib, Paclitaxel, Afuresertib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.